<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Parathyroid hormone (PTH) is a uremic toxin with multiple systemic effects including <z:e sem="disease" ids="C0005940" disease_type="Disease or Syndrome" abbrv="">bone disorders</z:e> (<z:e sem="disease" ids="C0035086" disease_type="Disease or Syndrome" abbrv="">renal osteodystrophy</z:e>), <z:hpo ids='HP_0003198'>myopathy</z:hpo>, <z:hpo ids='HP_0000707'>neurologic abnormalities</z:hpo>, <z:hpo ids='HP_0001903'>anemia</z:hpo>, <z:hpo ids='HP_0000989'>pruritus</z:hpo>, and <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000843'>Hyperparathyroidism</z:hpo> is common in CKD and results in significant morbidity and mortality if left untreated </plain></SENT>
<SENT sid="2" pm="."><plain>Clinical practice guidelines from the <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">Kidney Disease</z:e> Improving Global Outcomes initiative broadened the optimal PTH range to &gt;2 and &lt;9 times the upper limit of <z:mpath ids='MPATH_458'>normal</z:mpath> for the assay measured </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, the guidelines recommend following trends in PTH to determine the appropriate therapy </plain></SENT>
<SENT sid="4" pm="."><plain>These guidelines overcome issues with the assay variability and help clinicians make judgments when treating individual patients </plain></SENT>
<SENT sid="5" pm="."><plain>They also require frequent measurement in order to determine trends and implement appropriate treatments </plain></SENT>
</text></document>